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’INTRODUCTION
Cystic ﬁbrosis (CF), the most common channelopathy, is
caused by mutations in the cystic ﬁbrosis transmembrane con-
ductanceregulator(CFTR)gene.
1TheCFTRproteinworksasa
cAMP-activated plasma membrane Cl
  channel. As a matter of
fact, in CF, the lack of CFTR Cl
  channel function in the apical
membranes of many epithelial cells prevents the normal secre-
tion of Cl
  onto the epithelial surface. There is also a loss of
control of Na
þ channels, resulting in increased ﬂuid reabsorp-
tion. Consequently, there is a production of a thick and dehy-
drated mucus that is responsible for many of the most important
manifestationsofthediseaseintherespiratorytract.Inparticular,
the impairment of mucociliary clearance in the airways, due to
altered ion/ﬂuid transport, favors the colonization of the airway
surface by antibiotic-resistant bacteria. The presence of bacteria
triggers in turn a severe inﬂammatory response that irreversibly
damagesthelung.
2 4TheCFTRchannelcontains12transmem-
brane (TM) domains, with TM1, TM6 and TM12 contributing
to the formation of the ion pore. In addition, there are two
domains that bind cytoplasmic nucleotides (NBD1 and NBD2)
and a regulatory domain. The channel is regulated by binding of
ATP to NBDs and by the cAMP-dependent phosphorylation of
serine residues in the regulatory domain. Deletion of phenylala-
nine (ΔF508) in NBD1 occurs in nearly 70% of patients with
CF.
5 ΔF508 causes two types of problems: an impaired traﬃck-
ing of the protein and a defect in channel activity. The former
defectisthemostsevereconsequenceofthemutation,consisting
of the inability of the CFTR protein to exit the endoplasmic
reticulum. The latter defect appears instead as a partial response
to the cAMP activating stimulus. The two defects can be sep-
arately treated by pharmacological compounds called correctors
and potentiators, respectively.
6 9 Besides ΔF508, other CF
mutations are also sensitive to potentiators.
10
Antihypertensive1,4-dihydropyridines(1,4-DHPs)areawell-
known class of drugs that block voltage-dependent Ca
2þ chan-
nels. Many DHPs are also eﬀective potentiators of CFTR gating,
able to correct the defective activity of ΔF508 and other CFTR
mutants.
8 Activation of mutant CFTR by 1,4-DHPs occurs
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ABSTRACT: The pharmacology of the cystic ﬁbrosis trans-
membrane conductance regulator (CFTR) Cl
  channel has
attracted signiﬁcant interest in recent years with the aim to
search for rational new therapies for diseases caused by CFTR
malfunction. Mutations that abolish the function of CFTR
cause the life-threatening genetic disease cystic ﬁbrosis (CF).
The most common causeof CFisthe deletion of phenylalanine
508 (ΔF508) in the CFTR chloride channel. Felodipine,
nifedipine, and other antihypertensive 1,4-dihydropyridines
(1,4-DHPs) that block L-type Ca
2þ channels are also eﬀective
potentiators of CFTR gating, able to correct the defective
activity of ΔF508 and other CFTR mutants (Mol. Pharmacol. 2005, 68, 1736). For this purpose, we evaluated the ability of the
previously and newly synthesized 4-imidazo[2,1-b]thiazoles-1,4-dihydropyridines without vascular activity and inotropic and/or
chronotropic cardiac eﬀects (J. Med. Chem. 2008, 51, 1592) to enhance the activity of ΔF508-CFTR. Our studies indicate
compounds 17, 18, 20, 21, 38, and 39 as 1,4-DHPs with an interesting proﬁle of activity.3886 dx.doi.org/10.1021/jm200199r |J. Med. Chem. 2011, 54, 3885–3894
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through a mechanism that does not involve the inhibition of
Ca
2þ channels but possibly a direct interaction with the CFTR
protein itself.
9 Therefore, 1,4-DHPs represent an interesting
family of compounds for the development of eﬀective drugs
forCFtherapy.Indeed,theyhavebeenextensivelystudied,anda
large amount of information is available on their medicinal
chemistry properties.
11 However, optimization of potency for
CFTR versus Ca
2þ channels is required to minimize possible
side eﬀects. In fact, felodipine, nifedipine, and other 1,4-DHPs
used as drugs activate CFTR at concentrations that are consider-
ably higher than those eﬀective on Ca
2þ channels. A better
understanding of structural features required for CFTR acti-
vation may help in the development of more selective and
eﬀective DHP-based potentiators.
7 9 In a recent study, we
have published the synthesis, characterization, and functional
in vitro assays in cardiac tissues and smooth muscle (vascular
and nonvascular) of a number of 4-imidazo[2,1-b]thiazole-
1,4-dihydropyridines.
12 The binding properties for the novel
compounds have been investigated, and the interaction with
the binding site common to other 4-aryl-1,4-DHPs has been
demonstrated.Interestingly,thenovel4-aryldihydropyridines
are L-type calcium channel blockers with a peculiar pharma-
cological behavior. Indeed, the imidazo[2,1-b]thiazole system
is found to confer to the 1,4-dihydropyridine scaﬀold an
inotropic and/or chronotropic cardiovascular activity with a
high selectivity toward the nonvascular tissue. With this
information in mind, we designed and synthesized new
imidazo[2,1-b]thiazole derivatives 16 26, and in an attempt
to get major insights on structural features required for
speciﬁc CFTR activation, we screened a set of newly
(16 26) and previously synthesized 1,4-DHPs (27 47)
(Chart 1) using cell-based assays to determine their activity
as potentiator on ΔF508-CFTR. Moreover, we report func-
tional studies to deﬁne the cardiovascular activity proﬁle, the
relaxant activity on K
þ-depolarized guinea pig ileum long-
itudinal smooth muscle, and the bronchodilatation eﬀect on
guinea pig trachea with the aim to evaluate potency for CFTR
vs L-type calcium channels (LTCCs). In our analysis of
cardiac and smooth muscle function, we have also included
1,4-DHPs [48 (DHP-256), 49 (DHP-194), 50 (DHP-229)]
13
as reference compounds previously reported as CFTR poten-
tiators with reduced potency on Ca
2þ channels. Our results
show that modiﬁcations of the 1,4-DHP scaﬀold, particularly
inthe4-phenylringatC4,mayleadtocompoundswithhighly
improved selectivity as CFTR potentiators.
’CHEMISTRY
As shown in Scheme 1, the syntheses of the compounds
16 26 (Table 1) were accomplished starting from the bicyclic
heterocycles obtained by cyclocondensation of the appropriate
2-aminothiazoles 1 and 2 and bromoketones 3 and 4. Imidazo-
[2,1-b]thiazoles5 7gavethecorrespondingaldehydes8 10by
means of the Vilsmeier method. 1,4-DHPs 16 26 were synthe-
sized by means of the well-known Hantzsch reaction with the
appropriate aldehydes 8 15.
12,14 16 All ﬁnal products were
conﬁrmed with infrared spectra and
1H nuclear magnetic
resonance.
’PHARMACOLOGY
CFTRStudies.Theactivityof1,4-DHPsonΔF508-CFTRwas
tested in FRT cells coexpressing the mutant CFTR protein and
the halide-sensitive yellow fluorescent protein (HS-YFP) as
previously described.
8,13 Briefly, cells were previously incubated
at 27 C for 24 h to rescue the mutant protein from the
endoplasmic reticulum
8 and then acutely stimulated for 30 40
min with forskolin (20 μM) in the presence and absence of 1,4-
DHPs at three different concentrations (0.2, 2, and 20 μM).
CFTR activity was finally evaluated with a microplate reader by
continuously measuring the fluorescence in each well before and
after the addition of an I
  rich solution (final concentration of
100 mM), as previously described.
8,13 I
  influx through the
CFTR channel causes YFP quenching. Therefore, the rate of
fluorescence quenching reflects the extent of CFTR activity.
Accordingly,thereadingsfromeachwellwerenormalizedforthe
initialfluorescencevalueandthefluorescencedecayfollowingI
 
addition was fitted with an exponential function to derive the
maximal quenching rate (dF/dt). The quenching rate (QR) was
plotted against compound concentrations. The resulting dose 
response relationships were then fitted with the Hill equation to
estimate potency and maximal effect.
Functional Studies on Cardiac and Smooth Muscle Func-
tion. The pharmacological profile of compounds was derived in
guinea pig isolated left and right atria to evaluate their inotropic
and chronotropic effects, respectively, and in K
þ-depolarized
(80 mM) guinea pig vascular (aortic strips) and nonvascular
[ileum longitudinal smooth muscle (GPILSM)] to assess cal-
ciumantagonistactivity.Compoundswerechecked atincreasing
doses to evaluate the percent decrease of developed tension in
isolated left atrium driven at 1 Hz (negative inotropic activity),
Scheme 13887 dx.doi.org/10.1021/jm200199r |J. Med. Chem. 2011, 54, 3885–3894
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the percent decrease in atrial rate in spontaneously beating right
atrium (negative chronotropic activity), and the percent inhibi-
tion of calcium-induced contraction in K
þ-depolarized aortic
strips and GPILSM (vascular and nonvascular relaxant activity,
respectively). These details are reported in the Supporting
Information.
For some selected compounds (see Table 5) the characteriza-
tion was extended to guinea pig tracheal ring preparations
precontracted with carbachol (1 μM) to evaluate the induced
inhibition.
Data were analyzed using Student’s t-test and are presented as
the mean ( SEM.
17 Since the drugs were added in a cumulative
manner,thediﬀerencebetweenthecontrolandtheexperimental
valuesateachconcentrationwastestedforP<0.05.Thepotency
of drugs deﬁned as EC50 and IC50 was evaluated from log
concentration response curves (Probit analysis using Litchﬁeld
and Wilcoxon
17 or GraphPad Prism
18,19software) in the appro-
priate pharmacological preparations.
’RESULTS
A. CFTR Study. FRT cells expressing ΔF508-CFTR were
incubatedat27Cfor24htorescuethemutantproteinfromER,
thus improving its targeting to the plasma membrane. Subse-
quently the cells were stimulated with forskolin (20 μM) in the
presence and absence of 1,4-DHPs at different concentrations.
Under these conditions, the cAMP activating pathway is satu-
rated by the high forskolin concentration. Therefore, any in-
creaseinΔF508-CFTRactivitycausedbyacompoundabovethe
level reached with forskolin alone can be attributed to a
potentiator-like activity. We tested 4-imidazo[2,1-b]thiazole-
1,4-dihydropyridines as well as 48, 49, and 50, identified as
CFTR-selective potentiators from a previous study.
13 We also
includedgenisteinasanon-1,4-DHPpotentiator.Nifedipine,our
reference compound, shows a maximal activity of 58 and Kd =
2.9 ( 0.4 μM. Compounds 48 [Kd = 0.37 ( 0.07 μM], 49 [Kd =
0.17 ( 0.03 μM], and 50 [Kd = 0.40 ( 0.05 μM] show efficacy
comparable to that of nifedipine but, as reported previously,
13
with greatly improved potency. In particular, 49 has 17-fold
increased potency relative to nifedipine. Among 4-imidazo[2,1-b]-
thiazole-1,4-dihydropyridines,compounds23,24,30,32,35,37,
40 47 are inactive. In contrast, as shown in Figure 1, com-
pounds 17, 20, 21, 38, and 39 effectively induce CFTR activity,
with a maximal effect elicited at 20 μM comparable to that of
nifedipine and 48 50. However, the 4-imidazo[2,1-b]thiazole-
1,4-dihydropyridines appear significantly less potent given the
small activity induced at 0.2 μM. There are compounds such as
18 with apparently high potency [Kd = 0.18 ( 0.03] but with
partial activity (Emax = 42) (Table 2).
B. Functional Study in Cardiovascular System. All com-
pounds were tested for their cardiovascular profile in guinea pig
left atrium driven at 1 Hz and in spontaneously beating right
atrium to evaluate their negative inotropic and/or chronotropic
effects, respectively, and in 80 mM K
þ-depolarizing guinea pig
aortic strips to assess their vasorelaxant activity. Data are
collected in Table 3 for 16 26 and in Table S4 (Supporting
Information) for 27 47, using nifedipine, genistein, and48 50
as reference compounds. Nifedipine is active on all cardiovas-
cular parameters considered with selectivity for vascular smooth
muscle[IC50=0.009μM(CL0.003 0.02)].Incontrast,48 50
have no negative chronotropic and vascular effects. These three
compounds have selective negative inotropic activity with po-
tencyhigherthanthoseofnifedipine;inparticularthepotencyof
49 is EC50 = 0.0022 μM (CL 0.0014 0.0036).
In isolated vascular smooth muscle depolarized with 80 mM
K
þ, genistein is inactive. In cardiac isolated tissues genistein
induced negative inotropic and chronotropic activities with
about 1588-fold selectivity for negative inotropic potency
[EC50 = 0.028 μM (CL 0.021 0.037)] respective to negative
chronotropicpotency[EC50=44.48μM(CL34.98 56.61)].As
previously described, genistein up to 10 μM induced positive
inotropic activity.
20
All other compounds,except20,are devoid of vascular eﬀects.
The potency of 20 was not signiﬁcantly diﬀerent from that of
nifedipine[IC50=0.016μM(CL0012 0025),IC50=0.009μM
Table 1. 1,4-Dihydropyridines 16 47
compd x yR R 1
16 HCdCH CF3 C2H5
17 HCdCH 4-(CF3)-C6H4 CH3
18 HCdCH 4-(CF3)-C6H4 C2H5
19 H3CCdCCH3 4-(CF3)-C6H4 CH2CHdCH2
20 HCdCH 4-(OCF3)-C6H4 CH3
21 HCdCH 4-(OCF3)-C6H4 CH2CHdCH2
22 H3CCdCH C6H5 C2H5
23 H2C CH2 C6H5 CH3
24 HCdCH 2,5-(OCH3)-C6H3 CH2CHdCH2
25 H3CCdCH Cl C2H5
26 HCdCH 2,3,4-Cl3C6H2 C2H5
27
a HCdCH CF3 CH3
28
a H3CCdCH CF3 CH3
29
a ClCdCH CH3 CH3
30
a H3CCdCH CH3 CH3
31
a ClCdCH Cl CH3
32
a H3CCdCH Cl CH3
33
a HCdCCH3 Cl CH3
34
a H3CCdCCH3 Cl CH3
35
a HCdCH 2-(OCH3)C6H4 CH3
36
a HCdCH 3-(OCH3)C6H4 CH3
37
a HCdCH 2-(OCF3)C6H4 CH3
38
a HCdCH 3-(OCF3)C6H4 CH3
39
a HCdCH 3-(CF3)C6H4 CH3
40
a H3CCdCH 2,5-(OCH3)2C6H3 CH3
41
a ClCdCH 2,5-(OCH3)2C6H3 CH
42
a H5C2CdCH 2,5-(OCH3)2C6H3 CH3
43
a HCdCH 3,4-(OCH3)2C6H3 CH3
44
a ClCdCH 3,4,5-(OCH3)3C6H2 CH3
45
a ClCdCH 4-(NO2)-2,5-(OCH3)2C6H2 CH3
46
a HCdCH 6-(NO2)-2,5-(OCH3)2C6H2 CH3
47
a HCdCH 6-(NO2)-3,4-(OCH3)2C6H2 CH3
aReference 12.3888 dx.doi.org/10.1021/jm200199r |J. Med. Chem. 2011, 54, 3885–3894
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(CL 0003 0020), respectively] even if the intrinsic activity is
signiﬁcantly lower.
Compounds 28, 30, and 44 are also devoid of cardiac eﬀects.
In fact, their intrinsic activity on cardiac parameters is less than
50% for the inotropic and 40% for the chronotropic eﬀect at the
highest concentration studied.
A signiﬁcant group of compounds (11 of 32) expressed
negative inotropic selectivity: 16, 17, 24, 25, 29, 31 34, 37,
and 46, with potency between 0.039 and 1.96 μM. Among them,
nine compounds (17, 25, 29, 31 34, 37, and 46)w e r em o r e
potent than nifedipine [EC50 = 0.26 μM (CL 0.19 0.36)].
Derivatives 17, 29, 31, and 33 have negative inotropic eﬀect
about2.6timesgreaterthanthatofnifedipine.However,allthese
compounds have no intrinsic activity that exceeds 80%. There-
fore, the intrinsic activity is signiﬁcantly lower than that of
nifedipine considering the concentration needed to obtain the
maximal intrinsic activity with the exception of 16 and 17.
Most of the tested compounds (18, 19, 21, 23, 26, 27, 35, 36,
38 43, and 47) showed both negative inotropic and chrono-
tropic properties with diﬀerent selectivity. In particular, unlike
the reference nifedipine, none of these compounds showed
negative chronotropic selectivity. Compounds 19, 23, 27, 39,
and47,diﬀerentfromthereferencenifedipine,showedanegative
inotropic over chronotropic selectivity. In particular in 19, 23, 39,
and 47 are predominantly negative inotropic agents with a selec-
tivelyratioofabout33,22,12,and9,respectively.Derivatives35,38,
and 40 (Table S4) have only a weak negative inotropic selectivity.
Only compounds 22 and 45 have negative chronotropic selec-
tivity [EC50 =7 . 1 5μM (CL 4.30 10.01) and EC50 = 18.52 μM
(CL14.19 24.16) respectively] even though 286 and 446 times
less than that of nifedipine.
C. Functional Study in Guinea Pig Longitudinal Smooth
Muscle. It is well-known that calcium entry blockers such as
nifedipine have relevant inhibitory effects on nonvascular smooth
muscle.
21 All compounds were also tested in K
þ-depolarized
(80 mM) guinea pig ileum longitudinal smooth muscle to
evaluate both the effects on nonvascular smooth muscle and
the selective action by comparison with the cardiovascular
system. These data are collected in Table 4. For compounds
32, 36, 37, 44, and 46, these data are reported in the Supporting
Information (Table S5). As previously mentioned, among the
cardiovascular system, nifedipine showed a clear-cut vascular
potency and selectivity [EC50 = 0.009 μM (CL 0.003 0.02)].
However, with regard to the nonvascular smooth muscle, the
potencyofnifedipineincreases6timesifcomparedtothatmeasured
in aortic strips [EC50 = 0.0015 μM (CL 0.0011 0.0022)].
All three 1,4-DHPs previously described (48 50)
13 are able
to relax the intestinal smooth muscle but with a potency
signiﬁcantly lower than that of nifedipine. In the same prepara-
tion genistein induced relaxation with intrinsic activity similar
tothatof48butwithlowerpotency[IC50=9.95μM(CL8.01 
12.35); IC50 = 0.0015 μM (CL 0.0011 0.0022); respectively].
All the 1,4-DHPs bearing a imidazo[2,1-b]thiazole system at
C4areabletorelaxtheguineapiglongitudinalsmoothmuscleof
ileum. They show an increased activity in nonvascular smooth
muscle with respect to vascular smooth muscle with the excep-
tion of 18, which has a potency comparable to that of nifedipine
[IC50 = 0.00088 μM (CL 0.00021 0.0017); IC50 = 0.0015 μM
Figure1. CompoundeﬃcacyonΔF508-CFTR.Theeﬃcacyisobtainedfromdose responserelationshipsofYFPﬂuorescenceexperiments(mean(
SEM, n = 3).3889 dx.doi.org/10.1021/jm200199r |J. Med. Chem. 2011, 54, 3885–3894
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(CL0.0011 0.0022);respectively].Allothercompoundsareon
the whole less potent than the reference nifedipine. In particular,
compounds 17, 20, and 21 are about 3 times less potent than
nifedipine,whereas16,25,26,28,36,38,39,and45areabout65
times less potent. Compound 28 showed a selective activity for
the GPILSM, since it was ineﬀective on the cardiovascular
parameters studied.
D. Functional Study in Trachea. Compounds showing an
interesting activity profile as CFTR potentiators combined with
minor effects on cardiovascular parameters were also tested on
isolated tracheal rings to measure bronchodilatation (data of
selected compounds and references are collected in Table 5
with those of reference compounds). The compounds studied
have a different potency profile in guinea pig trachea smooth
muscle.
49 has a strong selectivity for the trachea compared to
nifedipine. Indeed, 49 is 163 times more potent than nifedipine.
48 and 50 have intrinsic activity e30%, while genistein has
intrinsic activity lover then 20%.
The new 1,4-DHPs studied showed a panel of various
activities. Among the compounds studied, 19 21, 26, 30, 37,
39, and 45 have intrinsic activity less than 50%. 17 and 18 have
the same intrinsic activity of nifedipine, while 38 reaches the
same intrinsic activity at a concentration 10 times higher.
However, the calculated potencies for 17, 18, and 38 were not
signiﬁcantly diﬀerent from that of nifedipine [EC50 = 0.061 μM
(CL 0.043 0.084), EC50 = 0.13 μM (CL 0.10 0.17), EC50 =
0.058 μM (CL 0.026 0.099), and EC50 = 0.096 μM (CL
0.070 0.13), respectively]. The relaxant potencies of 16, 25,
and 31 are lower than that of nifedipine (11-, 24-, and 38-fold,
respectively).
Interestingly, compound 28, which has no eﬀect on cardio-
vascular parameters, relaxes both intestinal and tracheal smooth
muscles.
’DISCUSSION
Our study had the main objective of identifying 1,4-DHPs
with optimal activity as potentiators of the CFTR Cl
  channel
and negligible eﬀects on voltage-dependent Ca
2þ channels
(VDCCs). In a previous paper, it was shown that these two
activitiesmightbeseparatedbymodifyingthesubstituentsof1,4-
DHP scaﬀold.
13 Indeed a cell-based functional assay approach
was used to identify compounds, such as 48 50, with high
potency and eﬃcacy on mutant CFTR and dramatically reduced
activity on VDCCs.
13 In the present study, we have proved these
results by testing these compounds on physiologically relevant
functions associated with Ca
2þ channel activity in heart, aorta
smooth muscle strips, and ileum. Our results in aortic strips
(Figure 2) demonstrate that the CFTR-selective 1,4-DHPs pre-
viously identiﬁed
13 indeed have low potency and eﬃcacy, com-
pared to an antihypertensive drug such as nifedipine, on the
contractility of smooth muscle of blood vessels. These com-
pounds, namely, 48 50, also have negligible negative chrono-
tropic activity on the guinea pig right atrium. In contrast, these
1,4-DHPs are similar to nifedipine as negative inotropic agents
andalsoasrelaxantagentsonintestinalsmoothmuscle(Tables3
and 4). These results may reﬂect a diﬀerent expression of Ca
2þ
channelsubtypesintissuesusedforfunctionalassays.Itisknown
that the activities of the cardiac calcium channel blockers are
related to their interaction with the R1-subunits of VDCCs. In
particular, the negative inotropic eﬀect is due to interaction with
the Cav1.2 isoform while the negative chronotropic eﬀect seems
to be related to interaction with the Cav1.3 isoform.
22 Further-
more, eﬀects of Ca
2þ channel blockers such as nifedipine on
vascularandnonvascularsmoothmusclecellsappeartobelinked
to the interaction with the Cav1.2 isoform.
23 Moreover, the
discovery that CFTR is expressed not only in epithelial cells but
also in the smooth muscle, where it may modulate contractility,
complicates the interpretation of results.
24 Toaddress this point,
we have also tested a classical non-1,4-DHP CFTR potentiator
Table 2. Activity of 1,4-DHPs and Genistein on
ΔF508-CFTR
a
compd Emax (ms
 1) nH mean Kd ( SEM (μM)
16 60 0.66 19.4 ( 2.4
17 64 2.15 3.2 ( 0.5
18 42 1.69 0.18 ( 0.03
19 42 1.14 0.32 ( 0.06
20 64 1.8 3.5 ( 0.7
21 60 1.09 4.8 ( 0.7
22 60 0.93 14.8 ( 1.9
23 inactive
b
24 inactive
b
25 60 0.86 8.4 ( 0.8
26 46 0.44 3.2 ( 0.6
27 60 1.89 28.3 ( 2.5
28 60 0.88 12.0 ( 1.6
29 60 1.55 42.9 ( 4.9
30 inactive
b
31 60 1.04 6.8 ( 1.0
32 inactive
b
33 60 0.82 21.4 ( 2.4
34 60 1.32 10.9 ( 1.8
35 inactive
b
36 60 1.5 34.2 ( 4.4
37 inactive
b
38 64 0.81 1.4 ( 0.1
39 65 1.01 2.8 ( 0.4
40 inactive
b
41 inactive
b
42 inactive
b
43 inactive
b
44 inactive
b
45 inactive
b
46 inactive
b
47 inactive
b
nifedipine 58 2.58 2.9 ( 0.4
48 62 0.97 0.37 ( 0.07
49 56 3.58 0.17 ( 0.03
50 59 1.18 0.40 ( 0.05
genistein 61 1.3 9.4 ( 1.1
aThe table reports the activity of compounds on ΔF508-CFTR
measured as I
  inﬂux (HS-YFP quenching rate). Dose response
relationships were generated, and the data were ﬁtted with the Hill
equation to obtain maximal eﬀect on quenching rate (Emax), Hill
coeﬃcient (nH), and apparent dissociation constant (Kd). For com-
pounds having low potency (i.e. 16, 22, 27, 29, 33, and 36) the ﬁt was
done with a forced Emax value of 60. Data were generated from three
independent determinations.
bInactive up to 20 μM.3890 dx.doi.org/10.1021/jm200199r |J. Med. Chem. 2011, 54, 3885–3894
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such as genistein. The ﬁnding that genistein has, at least in part,
a proﬁle similar to that of CFTR-selective 1,4-DHPs (i.e., low
activity on aorta and high relaxant eﬀect on ileum) suggests the
possibility that CFTR contributes to smooth muscle function in
some organs (Figure 2).
Here we have tested 4-imidazo[2,1-b]thiazole-1,4-dihydro-
pyridines as a possible new class of CFTR potentiators. Some
ofthesecompoundsareindeedhighlyeﬀectiveonΔF508-CFTR
andhavealowactivityonvascularsmoothmusclecellssimilarto
48 50. However, they have a relatively low potency as CFTR
potentiators (Kd in the micromolar range).
The evaluation of the screening tests on CFTR, on cardiac
tissue, and on vascular and nonvascular tissues for identiﬁcation
of the most promising molecules of the small library of the
imidazo[2,1-b]thiazole-1,4-DHP allows us to deﬁne some emer-
ging relationships.
As previously demonstrated, imidazo[2,1-b]thiazole substitu-
ents at C4 are able to change not only the cardiovascular
parameters
12 but also the CFTR activity (Figure 2). From a
quantitative standpoint, compounds bearing a 3- or 4-triﬂuor-
omethylphenyl group or a 3- or 4-triﬂuoromethoxyphenyl group
at the 6-position of the imidazo[2,1-b]thiazole (17, 18, 20, 21,
38, 39) are the most eﬀective on ΔF508-CFTR. A shift of the
triﬂuoromethoxyphenylgroupatposition2ofthephenylring37
or a replacement of the triﬂuoromethoxyphenyl group with a
methoxy group (35, 36) has a detrimental eﬀect on ΔF508-
CFTR.Alsotheintroductionofmorethanonemethoxygroupor
a nitro group on the phenyl ring drastically decreases activity on
ΔF508-CFTR (24, 40 47). All compounds with a triﬂuoro-
methyl group or a methyl group or chlorine in position 6 are less
CFTR-selective (16, 25, 27 34). The 2- and 3-positions of the
imidazo[2,1-b]thiazoleringmoderatelyaﬀecttheΔF508-CFTR
Table 3. Cardiovascular Activity of Tested Compounds
% decrease (mean ( SEM) EC50 of inotropic negative activity EC50 of chronotropic negative activity
compd
negative inotropic
activity
a
negative chronotropic
activity
b
EC50
c
(μM)
95% CL
( 10
-6)E C 50
c (μM)
95% CL
( 10
-6)
mean vasorelaxant
activity
dactivity ( SEM
16 93 ( 2.4 40 ( 1.4
e 1.07 0.76 1.49 48 ( 0.9
17 96 ( 3.7
f 33 ( 0.5
g 0.12 0.082 0.17 36 ( 2.1
h
18 90 ( 2.8
g 64 ( 1.1
h 0.033 0.026 0.044 0.15 0.071 0.67 6 ( 0.1
19 93 ( 2.2
i 52 ( 0.7 0.27 0.21 0.36 8.96 7.65 10.50 32 ( 1.9
20 89 ( 2.2 33 ( 1.6
k 2.33 1.90 2.66 60 ( 2.4
e,j
21 88 ( 0.1 77 ( 1.6
k 0.73 0.51 1.01 1.97 1.01 3.54 31 ( 2.8
e
22 44 ( 1.3
f 84 ( 1.6 7.15 4.30 10.01 5 ( 0.1
f
23 78 ( 2.2 90 ( 1.4
k 0.39 0.26 0.61 8.63 5.93 10.25 46 ( 3.1
24 81 ( 2.2
l 32 ( 1.1
e 0.34 0.23 0.48 31 ( 1.3
25 56 ( 1.7
g 36 ( 2.1
l 0.031 0.024 0.039 8 ( 0.2
26 90 ( 2.4
e 92 ( 2.7 0.43 0.31 0.57 0.61 0.41 0.89 17 ( 0.9
nifedipine 97 ( 2.0
f 85 ( 4.2
g 0.26 0.19 0.36 0.039 0.031 0.051 82 ( 1.3
e,m
48 80 ( 2.3
e 38 ( 0.4
l 0.029 0.021 0.040 17 ( 0.3
f
49 71 ( 1.1
h 5 ( 0.3 0.0022 0.0014 0.0036 12 ( 0.3
f
50 83 ( 1.4
e 6 ( 0.4 0.034 0.025 0.046 1 ( 0.01
f
genistein 71 ( 0.3
l 68 ( 2.1
k 0.028 0.021 0.037 44.48 34.95 56.61 22 ( 0.7
i
aDecreaseindevelopedtensiononisolatedguineapigleftatriumat10
 4M,expressedaspercentchangesfromthecontrol(n=5 6).Theleftatriawere
driven at 1 Hz.
bDecrease on atrial rate on guinea pig spontaneously beating isolated right atrium at 10
 5 M, expressed as percent changes from the
control(n=7 8).Pretreatmentheartraterangedfrom165to190beats/min.
cCalculatedfromlogconcentration responsecurves(Probitanalysisby
Litchﬁeld and Wilcoxon
17 with n =6  7). When the maximum eﬀect was <50%, the EC50 inotropic, EC50 chronotropic, and IC50 values were not
calculated.
dPercentinhibitionofcalcium-inducedcontractiononK
þ-depolarizedguineapigaorticstripat10
 4M(n=5 6).
eAt10
 6M.
fAt10
 5M.
gAt 10
 7 M.
hAt 5   10
 7 M.
iAt 5   10
 5 M.
jIC50 = 0.016 μM (CL 0.012 0.025).
kAt 10
 4 M.
lAt 5   10
 6 M.
mIC50 = 0.009 μM (CL
0.003 0.020).
Figure 2. Evaluation of selected compounds on CFTR, negative inotropic activity (INO), negative chronotropic activity (CHRONO), vasorelaxation
ofguineapigaorticstrips(AORTA),ileumlongitudinalsmoothmuscle(GPILSM),andtrachealsmoothmuscle(TRACHEA).Dataarenormalizedfor
the most eﬀective compound (100%) in each assay.3891 dx.doi.org/10.1021/jm200199r |J. Med. Chem. 2011, 54, 3885–3894
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activity more than the cardiovascular proﬁle. In both cases, the
aromaticity of the system must be kept as demonstrated by
compound 23 which is inactive in the assays. A comparison of
the ΔF508-CFTR activities of compounds 27, 28, 33,a n d34
seems to indicate that a methyl in position 2 of the heterocycle
canpositively inﬂuencetheeﬀect. This inﬂuence is greater if the
L-typecalciumchannelblockeractivityisconsidered(27vs28).
Theresultsinthefunctionalassaypointoutthatesteriﬁcationof
thecarboxylicfunctionsinpositions3and5ofthe1,4-DHPring
with bulky and more hydrophobic groups suchas allylic or ethyl
groups decreases potency on CFTR while two methyl groups
arebetterforCFTRpotentiators
13(seecompounds21and18vs
20 and 17). On the contrary, the introduction of ester, ethyl, or
allyl chains enhances L-type calcium channel blocker activity.
’CONCLUSIONS
Our study conﬁrms the possibility in the development of
1,4-DHPs with increased activity and selectivity as potentiators
of mutant CFTR and, at the same time, reduced activity as
inhibitors of voltage-dependent Ca
2þ channels of the cardiovas-
cular system and smooth muscle of nonvascular tissues (see
Figure 3). This is highly desirable for developing drugs able to
correctthebasicdefectincysticﬁbrosiswhilehavingminimalside
eﬀects. However, the 1,4-DHPs evaluated in this study still keep
someactivityinnonepithelialcells.Thismaybecausedbyresidual
activity on some types of Ca
2þ channels and/or expression of
CFTR in cardiac and smooth muscle cells. To further minimize
undesired eﬀects, it is possible to generate novel 1,4-DHPs
based on SAR obtained from the present and previous studies.
Ingeneraltheresultssuggestthatthecoreimidazo[2,1-b]thiazole
is conﬁrmedas a suitable heterocycletoexplore newpotentiators
of mutant CFTR. Of further interest is the eﬀect of the imidazo-
[2,1-b]thiazole substitution pattern on the proﬁle of biological
action. CFTR-selective potentiators might be better achieved by
aphenylringwithappropriatesubstituentsatthe6-positionofthe
imidazo[2,1-b]thiazole, while the substituents at the 2-position
can inﬂuence cardiovascular parameters to the same extent. In
addition, systemic eﬀects may be further minimized by consider-
ing delivery of 1,4-DHP potentiators via aerosol.
’EXPERIMENTAL SECTION
A. Chemistry. All the compounds prepared have a purity of at
least 95% asdetermined by combustion analysis. Themelting points are
Table 4. Relaxant Activity of Tested Compounds on
K
þ-Depolarized Guinea Pig Ileum Longitudinal Smooth
Muscle
compd mean activity
a ( SEM IC50
b (μM) 95% CL ( 10
-6)
16 90 ( 1.4
c 0.014 0.010 0.018
17 69 ( 3.6
d 0.0046 0.0036 0.0058
18 83 ( 1.3
e 0.00088 0.00021 0.0017
19 72 ( 2.3 0.46 0.36 0.61
20 73 ( 3.2
d 0.0033 0.0025 0.0042
21 90 ( 3.4
f 0.0053 0.0038 0.0073
22 83 ( 2.4 0.25 0.19 0.32
23 80 ( 1.1 0.26 0.20 0.33
24 96 ( 2.5
g 0.32 0.24 0.42
25 94 ( 1.4
g 0.057 0.043 0.076
26 77 ( 0.2 0.038 0.029 0.050
27 70 ( 2.3
h 0.21 0.14 0.31
28 92 ( 1.4 0.095 0.072 0.13
29 96 ( 3.3
g 0.55 0.19 0.93
30 70 ( 1.3
i 8.83 5.53 10.41
31 60 ( 1.4 0.68 0.55 0.84
33 97 ( 0.6
g 0.51 0.39 0.62
34 78 ( 1.2 0.32 0.24 0.41
35 88 ( 2.2
g 0.86 0.64 1.02
38 76 ( 1.3
f 0.018 0.010 0.097
39 96 ( 1.0
j 0.036 0.028 0.046
40 74 ( 1.4
i 4.89 3.74 6.40
41 91 ( 2.3
k 1.14 0.73 1.85
42 92 ( 1.1
i 2.16 1.03 2.94
43 90 ( 2.3 0.45 0.10 0.91
45 92 ( 2.2
j 0.074 0.057 0.097
47 86 ( 1.3
k 11.43 8.78 14.87
nifedipine 70 ( 0.36
e 0.0015 0.0011 0.0022
48 83 ( 2.6
i 0.23 0.17 0.31
49 52 ( 0.6
i 1.85 1.31 2.03
50 68 ( 1.5
i 0.94 0.64 1.38
genistein 84 ( 1.6
k 9.95 8.01 12.35
aPercent inhibition of calcium-induced contraction on K
þ-depolarized
(80mM)guineapiglongitudinalsmoothmuscleat10
 6M.
bCalculated
from logconcentration response curves (Probit analysis by Litchﬁeld
and Wilcoxon
17 with n =6  7). When the maximum eﬀect was <50%,
the IC50 values were not calculated.
cAt 10
 7 M.
dAt 10
 8 M.
eAt 5  
10
 9M.
fAt5 10
 8M.
gAt5 10
 6M.
hAt3 10
 7M.
iAt10
 5M.
jAt 5   10
 7 M.
kAt 5   10
 5 M.
Table 5. Bronchodilator Eﬀect of Same Compounds on
Guinea Pig Trachea
compd mean activity
a ( SEM IC50
b (μM) 95% CL ( 10
-6)
16 77 ( 1.7
c 1.11 0.87 1.23
17 67 ( 1.3 0.061 0.043 0.084
18 57 ( 2.4 0.13 0.10 0.17
19 33 ( 1.1
20 26 ( 2.1
21 38 ( 2.2
25 92 ( 1.4 2.34 1.89 2.89
26 40 ( 2.1
28 64 ( 1.6
d 0.031 0.023 0.041
30 27 ( 1.3
31 87 ( 1.5
c 3.66 1.21 4.74
37 47 ( 1.1
38 64 ( 2.5
c 0.058 0.026 0.099
39 19 ( 0.7
d
45 35 ( 2.2
c
nifedipine 62 ( 2.3 0.096 0.070 0.13
48 30 ( 2.6
49 68 ( 2.2 0.00059 0.00042 0.00083
50 29 ( 1.7
genistein 14 ( 1.1
aPercent inhibition of carbachol (1 μM) induced contraction on guinea
pig trachea at 10
 5 M. The 10
 5 M concentration gave the maximum
eﬀect for most compounds.
bCalculated from logconcentration 
response curves (Probit analysis by Litchﬁeld and Wilcoxon
17 with
n=6 7).Whenthemaximumeﬀectwas<50%,theIC50valueswerenot
calculated.
cAt 10
 4 M.
dAt 10
 7 M.3892 dx.doi.org/10.1021/jm200199r |J. Med. Chem. 2011, 54, 3885–3894
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uncorrected. Analyses (C, H, N) were within 0.4% of the theoretical
values. TLC was performed on Bakerflex plates (silica gel IB2-F). The
eluent was a mixture of petroleum ether 60 80 C/acetone in various
proportions. Kieselgel 60 (Merck) was used for flash chromatography.
The IR spectra were recorded in Nujol on a Nicolet Avatar 320 E.S.P.;
Rmax is expressed in cm
 1. The
1H NMR spectra were recorded on a
Varian Gemini (300 MHz); the chemical shift (referenced to solvent
signal)isexpressedinδ(ppm)andJinHz.Abbreviationsareasfollows:
th = thiazole,im =imidazole, ar =aromatic, py= pyridine,ex = Hlinked
to N that exchanged with D2O.
All solvents and reagents, unless otherwise stated, were supplied by
Sigma-Aldrich Chemical Co. Ltd. and were used as supplied. For a new
starting compound, see Table S1 in Supporting Information.
General Procedure for the Synthesis of the 1,4-Dihydropyridines
16 26. Methyl acetoacetate or ethyl acetoacetate or allyl acetoacetate
(2 mM) and 30% NH4OH (4 mM) were added to a stirred solution of
the appropriate aldehyde 8 15 (1 mM) dissolved in isopropyl alcohol
(50mL).Thereactionmixturewasrefluxedfor1 4days(accordingtoa
TLCtestacetone/petroleumether55 85C,1:9v/v,2:8v/v),andtoit
were added methyl acetoacetate or ethyl acetoacetate or allyl acetoace-
tate (4 mM) and 30% NH4OH (2 mM) every 12 h. After cooling, the
mixture was evaporated to dryness under reduced pressure. All the
derivativeswerepurifiedbyflashchromatographyonsilicagel(acetone/
petroleum ether 40 60 C from 1.9 to 4.6, v/v) to provide the pure
DHPs as a pale yellow syrup. The resulting oily residue was diluted with
cold acetone to afford a white solid collected by filtration for 16, 19,
21 26.For18theoilyresiduewasdilutedwithdiethylether.For17and
20 resulting oils were taken with acetone petroleum ether 1/1 v/v to
obtain a white solid collected by filtration.
Diethyl 2,6-Dimethyl-4-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-
yl)-1,4-dihydropyridine-3,5-dicarboxylate (16). 25% yield.
1HN M R :
0.96 (6H, t, COOCH2CH3, J = 7.1), 2.23 (6H, s, CH3), 3.90 (4H, q,
COOCH2CH3, J = 7.1), 5.52 (1H, s, py), 7.44 (1H, d, th, J =4 . 6 ) ,7 . 6 3
(1H, d, th, J= 4.6), 9.06 (1H, s, NH, ex D2O). Mp = 185 190 C. MW =
443.4435. Anal. (C19H20F3N3O4S) C, H, N.
Dimethyl 2,6-Dimethyl-4-(6-(4-(trifluoromethyl)phenyl)imidazo-
[2,1-b]thiazol-5-yl)-1,4-dihydropyridine-3,5-dicarboxylate (17). 25%
yield.
1HN M R :2 . 2 0( 6 H ,s ,C H 3), 3.18 (6H, s, COOCH3), 5,72 (1H, s,
py),7.27(1H,m,th),7.33(1H,m,th),7.79(2H,d,ar,J=5.2),8.09(2H,d,
ar, J = 5.2), 9.13 (1H, s, NH, ex D2O). Mp = 227. MW = 491.1126. Anal.
(C23H20F3N3O4S) C, H, N.
Diethyl 2,6-Dimethyl-4-(6-(4-(trifluoromethyl)phenyl)imidazo[2,1-
b]thiazol-5-yl)-1,4-dihydropyridine-3,5-dicarboxylate (18). 30% yield.
1HN M R :0 . 8 1( 6 H ,t ,C O O C H 2CH3, J = 7.1), 2.15 (6H, s, CH3), 3.75
(4H, m, COOCH2CH3), 5.65 (1H, s, py), 7.32 (1H, d, th, J = 4.4), 7.43
(1H, d, th, J = 4.4), 7.70 (2H, d, ar, J = 8.4), 8.04 (2H, d, ar, J = 8.4), 8.98
(1H, s, NH, ex D2O). Mp = 175 180. MW = 519.5400. Anal.
(C25H24F3N3O4S) C, H, N.
Diallyl 4-(2,3-Dimethyl-6-(4-(trifluoromethyl)phenyl)imidazo[2,1-
b]thiazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (19).
10% yield.
1HN M R :1 . 8 8( 6 H ,s ,C H 3), 2.31 (3H, s, CH3), 2.64 (3H, s,
CH3), 4.31 (2H, dd, J = 5.45, J =1 3 . 6 5 ,CH2CHdCH2), 4.50 (2H, dd,
J =5 . 4 5 ,J = 13.65, CH2CHdCH2), 4.88 (2H, dd, J = 1.55, J = 17.2,
CH2CHdCH2),5.00(2H,dd,J=1 . 5 5 ,J= 10.5, CH2CH=CH2), 5,43 (1H,
s,py),5.58(2H,m,CH2CHdCH2),7.30(2H,d,ar,J=8.2),7.68(2H,d,ar,
J=8.2),8.18(1H,s,NH,exD2O). Mp = 165 170. MW = 571.6149. Anal.
(C29H28F3N3O4S) C, H, N.
Dimethyl 2,6-Dimethyl-4-(6-(4-(trifluoromethoxy)phenyl)imidazo-
[2,1-b]thiazol-5-yl)-1,4-dihydropyridine-3,5-dicarboxylate(20).20%yield.
1HN M R :2 . 2 0( 6 H ,s ,C H 3), 3.21 (6H, s, COOCH3), 5.67 (1H, s, py),
7.27 (1H, d, th, J=3.1),7.32(1H,d,th,J=3.1),7.42(2H,d,ar,J=5.7), 7.96
(2H, d, ar, J = 5.7), 9.08 (1H, s, NH, ex D2O). Mp = 217. MW = 507.1075.
Anal. (C23H20F3N3O5S) C, H, N.
Diallyl 2,6-Dimethyl-4-(6-(4-(trifluoromethoxy)phenyl)imidazo[2,1-
b]thiazol-5-yl)-1,4-dihydropyridine-3,5-dicarboxylate (21). 10% yield.
1HN M R :2 . 1 6( 6 H ,s ,C H 3), 4.15 (2H, dd, J = 5.55, J =1 3 . 5 ,
Figure 3. (a) Comparison of potencies of diﬀerent biological parameters for compounds with the best, interesting proﬁle. (b) Reference compounds.
Data are expressed as  logpotency ( CL.3893 dx.doi.org/10.1021/jm200199r |J. Med. Chem. 2011, 54, 3885–3894
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CH2CHdCH2), 4.33 (2H, dd, J = 5.55, J = 13.5, CH2CHdCH2), 4.91
(2H,dd,J=1.5,J=10.35, CH2CHdCH2),4.98(2H,dd,J=1.5,J=10.35,
CH2CHdCH2),5.54(2H,m,CH2CHdCH2),5.62(1H,s,py),7.28(1H,
d, th, J=4.35),7.36(2 H,d,ar ,J=8.7),7.38(1H, d,th,J=4.35),7.86(2H,
d, ar, J = 8.7), 9.00 (1H, s, NH, ex D2O). Oil. MW = 559.1388. Anal.
(C27H24F3N3O5S) C, H, N.
Diethyl 2,6-Dimethyl-4-(2-methyl-6-phenylimidazo[2,1-b]thiazol-5-
yl)-1,4-dihydropyridine-3,5-dicarboxylate (22). 20% yield.
1HN M R :
0.85 (6H, t, COOCH2CH3, J =7 . 0 5 ) ,2 . 1 2( 6 H ,s ,C H 3), 2.42 (3H, s,
CH3), 3.71 (2H, q, COOCH2CH3, J =7 . 0 5 ) ,3 . 8 1( 2 H ,q ,C O O CH2CH3,
J=7 . 0 5 ),5 . 5 4(1 H ,s ,p y ),7 . 2 5(3 H ,m ,t hþ ar), 7.36 (1H, t, ar, J= 6.95),
7.72 (2H, d, ar, J = 6.95), 8.80 (1H, s, NH, ex D2O). Mp = 205. MW =
465.1722. Anal. (C25H27N3O4S) C, H, N.
Dimethyl 2,6-Dimethyl-4-(6-phenyl-2,3-dihydroimidazo[2,1-b]thiazol-
5-yl)-1,4-dihydropyridine-3,5-dicarboxylate (23). 30% yield.
1HN M R :
2.16 (6H, s, CH3), 3.23 (6H, s, COOCH3), 3.89 (2H, d, thn, J =
6 . 2 ) ,3 . 9 8( 2 H ,d ,t h n ,J = 6.2), 5.44 (1H, s, py), 7.23 (1H, t, ar, J =
7.3),7.35 (2H, t, ar, J = 7.3), 7.70 (2H, d, ar, J = 7.3), 8.82 (1H, s,
NH, ex D2O). Mp = 245. MW = 424.4966. Anal. (C22H22N3O4S)
C, H, N.
Diallyl 4-(6-(2,5-Dimethoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-
2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (24). 15% yield.
1H NMR: 1.92 (6H, s, CH3), 3.46 (3H, s, OCH3), 3.69 (3H, s, OCH3),
4.35 (2H, dd, J = 5.15, J = 13.95, CH2CHdCH2), 4.48 (2H, dd, J =
5.15, J = 13.95, CH2CHdCH2), 4.86 (2H, dd, J = 1.4, J = 17.2,
CH2CHdCH2), 4.98 (2H, dd, J = 1.4, J = 10.6, CH2CHdCH2), 5.09
(1H, s, py), 5.69 (2H, m, CH2CHdCH2), 6.44 (1H, s, ar), 6.86 (1H, s,
ar), 7.11 (1H, d, th, J = 4.6), 7.74 (1H, d, th, J = 4.6), 8.14 (1H, s, NH,
ex D2O). Mp = 200 205. MW = 535.6157. Anal. (C28H29N3O6S)
C, H, N.
Diethyl 4-(6-Chloro-2-methylimidazo[2,1-b]thiazol-5-yl)-2,6-di-
methyl-1,4-dihydropyridine-3,5-dicarboxylate (25). 75% yield.
1HNMR: 0.99 (6H, t, COOCH2CH3, J = 7.2), 2.25 (6H, s, CH3),
2.42 (3H, s, CH3), 3.90 (4H, m, COOCH2CH3), 5.12 (1H, s, py), 7.58
(1H,s,th),9.04(1H,s,NH,exD2O).Mp=175.MW=423.1019.Anal.
(C19H22ClN3O4S) C, H, N.
Diethyl 2,6-Dimethyl-4-(6-(2,3,4-trichlorophenyl)imidazo[2,1-b]-
thiazol-5-yl)-1,4-dihydropyridine-3,5-dicarboxylate (26). 20% yield.
1H NMR: 0.93 (6H, t, COOCH2CH3, J = 7.1), 1.94 (6H, s, CH3), 3.91
(4H, m, COOCH2CH3), 5.07 (1H, s, py), 7.05 (1H, d, ar, J = 8.4), 7.26
(1H,d,th,J=4.4),7.66(1H,d,ar,J=8.4),7.95(1H,d,th,J=4.4),8.21
(1H, s, NH, ex D2O). Mp = 230 235. MW = 554.8765. Anal.
(C24H22Cl3N3O4S) C, H, N.
B. CFTR Assays. For details, see Supporting Information, sec-
tion S10.
C. Functional Studies. For details, see Supporting Information,
section S11.
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